Physiologically‐based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID‐19

Pregnant individuals are at high risk for severe illness from COVID‐19, and there is an urgent need to identify safe and effective therapeutics for this population. Remdesivir (RDV) is a SARS‐CoV‐2 nucleotide analog RNA polymerase inhibitor. Limited RDV pharmacokinetic (PK) and safety data are avail...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaomei I., Dallmann, André, Brooks, Kristina, Best, Brookie M., Clarke, Diana F., Mirochnick, Mark, van den Anker, John N., Capparelli, Edmund V., Momper, Jeremiah D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877749/
https://www.ncbi.nlm.nih.gov/pubmed/36479969
http://dx.doi.org/10.1002/psp4.12900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877749/
https://www.ncbi.nlm.nih.gov/pubmed/36479969
http://dx.doi.org/10.1002/psp4.12900

Ejemplares similares